Regulus Therapeutics this week announced the presentation of preclinical data showing that circulating microRNAs may be effective biomarkers for determining tumor growth and systemic response disease in liver cancer.
SAN DIEGO (GenomeWeb News) — MicroRNAs are cropping up in different aspects of cancer research, according to a session at the American Association for Cancer Research annual meeting held here this week.
A little less than a year after it lost its partner for its preclinical hepatitis C therapy RG-101, Regulus Therapeutics announced last week that AstraZeneca has stepped away from the companies' program to develop an atherosclerosis drug targeting microRNA-33.
Regulus Therapeutics this week announced that has formally added its preclinical program in the rare kidney disease Alport syndrome to its drug-development pipeline — a move widely expected based on company comments and recently released animal data linking microRNA-21 to the dis
Regulus Therapeutics has named David Szekeres as its chief business officer and general counsel.
In the new role, he will be responsible for business development, strategic planning, and legal efforts, Regulus said.
The National Institutes of Health this month awarded more than $800,000 in research funding to support the work of four researchers, including two that have collaborated with Regulus Therapeutics, who are examining the role of microRNAs in various aspects of cardiovascular diseas